Skip to main content
SpringerLink
Log in

The criteria of the Italian Federation of Thrombosis Centres on DOACs: a “real world” application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist

  • IM - ORIGINAL
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the number of patients with nonvalvular atrial fibrillation (NVAF), anticoagulated with vitamin K antagonists (VKA), and monitored in our Thrombosis Centre, who could replace VKA with direct oral anticoagulants (DOACs) based on the Italian Federation of Thrombosis Centres (FCSA) consensus criteria. A total of 525 NVAF patients treated with VKA were studied. Therapeutic range (TTR) assessment and a capillary test for serum creatinine measure were carried out. The patients’ preference was evaluated through the administration of a dedicated questionnaire. A history of intracranial bleeding was also taken into account. DOACs would cover 29 % of the patients considering a TTR <70 %; the percentage falls to 10 % if a TTR <55 % is considered. Only 20 % of the patients would move from VKA to DOACs because of the lack of an antidote and laboratory checks during DOACs therapy. Thirty-three percent of patients were worried that they would forget to take the tablets twice a day. About 2 % of patients could not use DOACs since their glomerular filtration rate was less than 30 ml/min, while in 23.6 %, a reduction in the daily dose of DOACs would have been required due to renal failure. TTR assessment, renal function and a previous history of intracranial bleeding would reduce the percentage of patients who could switch from VKA to DOACs, but it is the patients’ preference that strongly influences the percentage of those who would benefit from DOACs treatment. However, if laboratory controls were available, it would rise considerably.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alberts MJ, Eikelboom JW, Hankey GJ (2012) Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 11:1066–1081

    Article  CAS  PubMed  Google Scholar 

  2. Giugliano RP, Ruff CT, Braunwald E, Murlhy SA, Wiviott SD, Halperin JL, ENGAGE AF-TIMI 48 Investigators et al (2013) Edoxaban versus Warfarin in patients with Atrial Fibrillation. New Eng J Med 369:2093–2104

    Article  CAS  PubMed  Google Scholar 

  3. Liew A, Douketis J (2013) Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med 8:477–484

    Article  PubMed  Google Scholar 

  4. Tripodi A (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035

    Article  CAS  PubMed  Google Scholar 

  5. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P (2013) Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP). Arch Cardiovasc Dis 106:382–393

    Article  PubMed  Google Scholar 

  6. Ho PM, Bryson CL, Rumsfeld JS (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119:3028–3035

    Article  PubMed  Google Scholar 

  7. Rubboli A, Oldgren J, Marìn F, Lip G (2013) Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Intern Emerg Med 8:673–680

    Article  PubMed  Google Scholar 

  8. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C, Italian Federation of Thrombosis Centres (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centres (FCSA). Thromb Haemost 106:868–876

    Article  CAS  PubMed  Google Scholar 

  9. Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F (2000) The management of oral anticoagulant therapy: the patient’s point of view. Thromb Haemost 83:49–53

    CAS  PubMed  Google Scholar 

  10. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidb√ºchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt F (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747

    Article  PubMed  Google Scholar 

  11. Esmon CT (2012) What did we learn from new oral anticoagulant treatment ? Thromb Res 130(Suppl 1):S41–S43

    Article  PubMed Central  PubMed  Google Scholar 

  12. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RELY trial. Lancet 376:975–983

    Article  CAS  PubMed  Google Scholar 

  13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    Article  CAS  PubMed  Google Scholar 

  14. Carstensen CA, Nagel R, Knoll E, Wisser H, Weidemann G, Riesen WF, Seiler D, Nagel D (1993) Development and evaluation of a reagent carrier with a new reaction sequence for the determination of creatinine in blood, plasma, serum and urine. Eur J Clin Chem Clin Biochem 31:335–346

    CAS  PubMed  Google Scholar 

  15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239

    CAS  PubMed  Google Scholar 

  16. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6:65–70

    Google Scholar 

  17. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological) 57:289–300

    Google Scholar 

  18. Agencia espagnola de medicamentos y productos sanitarios. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales en la prevenciòn del ictus y la embolia sistèmica en pacientes con fibrilaciòn auricular no valvular. Fecha de publicaciòn: 24 de septiembre de 2012

  19. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E (2013) Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis 2013:640723 (Epub 2013 Dec 22)

  20. Barcellona D, Fenu L, Cornacchini S, Marongiu F (2013) Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home. J Telemed Telecare 19:298–301

    Article  PubMed  Google Scholar 

  21. Osterberg L, Blaschke T (2005) Adherence to medication. New Engl J Med 353:487–497

    Article  CAS  PubMed  Google Scholar 

  22. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63:321–328

    Article  CAS  PubMed  Google Scholar 

  23. Cohen D (2014) Concerns over data in key dabigatran trial. BMJ 349:g4747

    Article  PubMed  Google Scholar 

  24. Charlton B, Redberg R (2014) The trouble with dabigatran. BMJ 349:g4681

    Article  PubMed  Google Scholar 

  25. Cohen D (2014) Dabigatran: how the drug company withheld important analyses. BMJ 349:g4670

    Article  PubMed  Google Scholar 

  26. Barcellona D, Contu P, Marongiu F (2002) Patient education and oral anticoagulant therapy. Haematologica 87:1081–1086

    PubMed  Google Scholar 

  27. Kneeland PP, Fang MC (2010) Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 4:51–60

    PubMed Central  PubMed  Google Scholar 

  28. Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G (2014) Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res 133:699–704

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Doctors Igor Portoghese and Maura Galletta for their helpful advice and Mr. Barry Mark Wheaton for his editing assistance.

Conflict of interest

The authors have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Department of Medical Sciences, University of Cagliari, Cagliari, Italy

    Doris Barcellona, Miro Luzza, Nicola Battino, Lara Fenu & Francesco Marongiu

  2. Department of Medical Sciences, Cittadella Universitaria, Monserrato, CA, Italy

    Doris Barcellona

Authors
  1. Doris Barcellona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miro Luzza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicola Battino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lara Fenu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Marongiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doris Barcellona.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barcellona, D., Luzza, M., Battino, N. et al. The criteria of the Italian Federation of Thrombosis Centres on DOACs: a “real world” application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist. Intern Emerg Med 10, 157–163 (2015). https://doi.org/10.1007/s11739-014-1155-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-014-1155-7

Keywords

Search

Navigation